This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
BioWest Therapeutics, Inc.
Drug Names(s): MBI-3253, MX-3253
Description: MX-3253 (celgosivir) is an alpha-glucosidase I inhibitor.
Deal Structure: In July 2005, Migenix completed a Material Transfer and License Option Agreement with Schering-Plough Corporation related to MX-3253. Under the terms of the Agreement, Schering-Plough will supply Pegetron as well as provide certain technical and laboratory support and other services for MX-3253 development. In addition, the Agreement grants Schering-Plough limited periods of exclusivity for data review of clinical trial results and for the negotiation of a license agreement.
In June 2007, Migenix received notice that Schering-Plough will not enter into a second period of exclusivity to negotiate terms of a license agreement for celgosivir. Migenix therefore became free to advance discussions with other interested parties. Schering has expressed a willingness to consider providing Migenix with guidance on study design and drug supplies in support of celgosivir's further clinical development.
In January 2009, Migenix entered into an exclusive option agreement with...See full deal structure in Biomedtracker
Pink Sheet Licensing In Brief
Additional information available to subscribers only: